SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1.

Adipocytes Cancer PDHA1 ROS SHP2

Journal

Journal of cell communication and signaling
ISSN: 1873-9601
Titre abrégé: J Cell Commun Signal
Pays: Netherlands
ID NLM: 101308338

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 12 05 2022
accepted: 10 08 2022
medline: 9 9 2022
pubmed: 9 9 2022
entrez: 8 9 2022
Statut: ppublish

Résumé

Adipocytes are the most abundant cell type in the adipose tissue, and their dysfunction is a significant driver of obesity-related pathologies, such as cancer. The mechanisms that (1) drive the maintenance and secretory activity of adipocytes and (2) mediate the cancer cellular response to the adipocyte-derived factors are not fully understood. To address that gap of knowledge, we investigated how alterations in Src homology region 2-containing protein (SHP2) activity affect adipocyte function and tumor crosstalk. We found that phospho-SHP2 levels are elevated in adipose tissue of obese mice, obese patients, and differentiating adipocytes. Immunofluorescence and immunoprecipitation analyses as well as in-silico protein-protein interaction modeling demonstrated that SHP2 associates with PDHA1, and that a positive association promotes a reactive oxygen species (ROS)-driven adipogenic program. Accordingly, this SHP2-PDHA1-ROS regulatory axis was crucial for adipocyte maintenance and secretion of interleukin-6 (IL-6), a key cancer-promoting cytokine. Mature adipocytes treated with an inhibitor for SHP2, PDHA1, or ROS exhibited an increased level of pro-lipolytic and thermogenic proteins, corresponding to an increased glycerol release, but a suppression of secreted IL-6. A functional analysis of adipocyte-cancer cell crosstalk demonstrated a decreased migration, invasion, and a slight suppression of cell cycling, corresponding to a reduced growth of pancreatic cancer cells exposed to conditioned media (CM) from mature adipocytes previously treated with inhibitors for SHP2/PDHA1/ROS. Importantly, PDAC cell growth stimulation in response to adipocyte CM correlated with PDHA1 induction but was suppressed by a PDHA1 inhibitor. The data point to a novel role for (1) SHP2-PDHA1-ROS in adipocyte maintenance and secretory activity and (2) PDHA1 as a regulator of the pancreatic cancer cells response to adipocyte-derived factors.

Identifiants

pubmed: 36074246
doi: 10.1007/s12079-022-00691-1
pii: 10.1007/s12079-022-00691-1
pmc: PMC10409927
doi:

Types de publication

Journal Article

Langues

eng

Pagination

575-590

Subventions

Organisme : NCI NIH HHS
ID : P30 CA168524
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231052
Pays : United States
Organisme : NCI NIH HHS
ID : CA231052
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM103326
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA201135
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1943-50
pubmed: 22628433
Sci Rep. 2017 Mar 28;7(1):461
pubmed: 28352079
J Am Coll Surg. 2009 May;208(5):989-94; discussion 994-6
pubmed: 19476877
J Neurochem. 2012 Aug;122(4):834-43
pubmed: 22671569
Mol Cell. 2020 Oct 15;80(2):263-278.e7
pubmed: 33022274
Biochemistry. 2003 May 13;42(18):5461-8
pubmed: 12731888
Ann Oncol. 2015 Nov;26(11):2257-66
pubmed: 26347100
J Biol Chem. 2018 Jul 13;293(28):11143-11153
pubmed: 29853638
J Exp Clin Cancer Res. 2019 May 28;38(1):223
pubmed: 31138258
Mol Cell Biol. 2016 Jun 29;36(14):1961-76
pubmed: 27185873
Science. 1993 Mar 12;259(5101):1611-4
pubmed: 7681217
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14802-7
pubmed: 11752427
Nat Genet. 2018 Feb;50(2):219-228
pubmed: 29335542
Life Sci. 2015 Jan 15;121:97-103
pubmed: 25498896
Oncotarget. 2016 Oct 4;7(40):65982-65992
pubmed: 27602757
Oncotarget. 2017 Aug 3;8(49):85378-85391
pubmed: 29156726
Nat Rev Gastroenterol Hepatol. 2019 May;16(5):263
pubmed: 30953033
J Clin Endocrinol Metab. 2004 Mar;89(3):1352-8
pubmed: 15001633
Cancer Metab. 2015 Jan 25;3(1):1
pubmed: 25621173
Sci Transl Med. 2021 Apr 28;13(591):
pubmed: 33910978
Nat Commun. 2017 Nov 6;8(1):1322
pubmed: 29109438
Nat Cell Biol. 2017 Aug;19(8):974-987
pubmed: 28737771
J Biol Chem. 2012 Jun 22;287(26):21904-13
pubmed: 22511784
J Vis Exp. 2013 Mar 28;(73):
pubmed: 23568137
Surgery. 2009 Aug;146(2):258-63
pubmed: 19628082
Science. 1993 Mar 12;259(5101):1607-11
pubmed: 8096088
Int J Mol Med. 2007 Jun;19(6):895-900
pubmed: 17487421
IEEE Int Conf Comput Adv Bio Med Sci. 2011 Feb;2011:13-18
pubmed: 27818847
Nat Med. 2011 Oct 30;17(11):1498-503
pubmed: 22037646
Diabetes. 2018 Nov;67(11):2456-2465
pubmed: 30158241
J Biol Chem. 2015 Feb 13;290(7):3894-909
pubmed: 25538234
PLoS One. 2013 May 10;8(5):e63152
pubmed: 23675459
J Mol Endocrinol. 2014 Jun;52(3):R199-222
pubmed: 24577718
Oxid Med Cell Longev. 2019 Feb 7;2019:4532592
pubmed: 30881593
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9474-E9482
pubmed: 29078316
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W310-4
pubmed: 16845016
Proteins. 2005 Aug 1;60(2):296-301
pubmed: 15981259
BMB Rep. 2012 Dec;45(12):700-6
pubmed: 23261055
Nat Rev Cancer. 2021 Jul;21(7):412
pubmed: 34089012
J Exp Med. 2019 Feb 4;216(2):337-349
pubmed: 30610104
Nat Commun. 2017 Dec 18;8(1):2168
pubmed: 29255148
Stem Cells Dev. 2013 Mar 15;22(6):878-88
pubmed: 23025577
Mol Cell Biol. 2017 Aug 28;37(18):
pubmed: 28652267
FASEB J. 2019 Oct;33(10):11528-11540
pubmed: 31370677
Mol Med Rep. 2020 Sep;22(3):2235-2244
pubmed: 32705242
Cell. 2010 Jan 22;140(2):197-208
pubmed: 20141834
Nat Med. 2018 Jul;24(7):954-960
pubmed: 29808009
FASEB J. 2021 Jan;35(1):e21106
pubmed: 33165997
Front Immunol. 2018 Nov 05;9:2556
pubmed: 30455701
J Exp Med. 2019 Jun 3;216(6):1345-1358
pubmed: 31053611
Nat Commun. 2018 Apr 25;9(1):1646
pubmed: 29695802
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4494-503
pubmed: 25288766
J Hematol Oncol. 2013 Feb 25;6:19
pubmed: 23442817
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E79-88
pubmed: 23236157
J Clin Endocrinol Metab. 2001 May;86(5):2281-8
pubmed: 11344240
Clin Cancer Res. 2015 Aug 1;21(15):3522-8
pubmed: 25700304
Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):2751-2760
pubmed: 31980524
PLoS One. 2015 Apr 28;10(4):e0126686
pubmed: 25919692
Nat Commun. 2017 Mar 10;8:14706
pubmed: 28281525
Ann Oncol. 2012 Apr;23(4):843-52
pubmed: 21890910
Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16064-9
pubmed: 15520383
Cell Death Dis. 2022 Feb 4;13(2):114
pubmed: 35121743
Nat Commun. 2019 Mar 29;10(1):1444
pubmed: 30926899
J Clin Invest. 2004 Dec;114(12):1752-61
pubmed: 15599400
Cell Res. 2007 Jan;17(1):37-41
pubmed: 17211446
J Infect Dis. 2016 Aug 15;214(4):625-33
pubmed: 27330052
Adipocyte. 2018;7(3):226-228
pubmed: 30001663

Auteurs

Appolinaire A Olou (AA)

Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA. aolou@kumc.edu.

Joe Ambrose (J)

Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

Jarrid L Jack (JL)

Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

McKinnon Walsh (M)

Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

Mariana T Ruckert (MT)

Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

Austin E Eades (AE)

Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

Bailey A Bye (BA)

Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

Prasad Dandawate (P)

Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

Michael N VanSaun (MN)

Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA. mvansaun@kumc.edu.

Classifications MeSH